Q2 FY2026 · ended Jun 30, 2026 · Revenue $0, +100.0% YoY · Filed Aug 19, 2026
Endovia Health Sciences, Inc. (EDVA) files with the SEC under industry code 2080, Beverages. In Q2 of fiscal 2026, the quarter ended Jun 30, 2026, it reported revenue of $0 and a net loss of $2.1 million.
Revenue
$0
+100.0% vs year-ago quarter
Net income
$-2.05M
+75.8% vs year-ago quarter
Operating cash flow
$-1.09M
-98.1% vs year-ago quarter
Free cash flow
$-2.65M
EPS
$-0.67
+96.3% vs year-ago quarter
Dividend per share
None
Shares outstanding
6.41M
+199.2% vs year-ago quarter
Net cash
$343,286
Q1 FY2026
Operating margin
-43665.5%
TTM
Company profile
- Industry
- Beverages (SIC 2080)
- Listed as
- EDVA (NYSE)
- Fiscal year ends
- December 31
- Incorporated in
- NV
- Headquarters
- Fort Lauderdale, FL
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1553788
- Former names
- SPLASH BEVERAGE GROUP, INC. (until Aug 21, 2026); Canfield Medical Supply, Inc. (until Aug 5, 2020)
Other Beverages companies
- Coca Cola Co KO
- Pepsico Inc PEP
- Diageo PLC DEO
- Keurig Dr Pepper Inc. KDP
- Ambev S.A. ABEV
- Constellation Brands, Inc. STZ
- Brown Forman Corp BF-B
- Primo Brands Corp PRMB
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
Q2 FY2025 Jun 30, 2025 |
|---|---|---|---|---|---|
| Revenue | $0 | $4,224 | -$365,206 | $393,072 | -$23,406 |
| Operating income | -$2.0M | -$978,970 | -$976,411 | -$9.5M | -$1.5M |
| Net income | -$2.1M | -$2.1M | -$3.2M | -$9.9M | -$8.5M |
| Diluted EPS | -$0.67 | -$0.47 | -$1.15 | -$4.51 | -$17.88 |
| Operating cash flow | -$1.1M | -$930,492 | -$991,221 | -$2.5M | -$551,123 |
| Total assets | $1.1M | $769,953 | $965,694 | $22.5M | $22.2M |
| Total liabilities | $16.8M | $17.0M | $16.3M | $15.7M | $13.5M |
| Stockholders' equity | -$15.7M | -$16.2M | -$15.3M | $6.8M | $8.7M |
| Cash and investments | $242,702 | $381,195 | $281,435 | $265,667 | $17,213 |
| Total debt | — | $37,909 | $57,114 | $190,757 | $262,788 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Material agreement
|
Oct 27, 2026 | Oct 22, 2026 |
| 8-K |
Current report
Material agreement
|
Oct 15, 2026 | Oct 15, 2026 |
| 8-K |
Current report
Unregistered share sale
|
Oct 6, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Oct 5, 2026 | Oct 5, 2026 |
| 8-K |
Current report
Material agreement, Unregistered share sale
|
Sep 24, 2026 | Sep 18, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Sep 22, 2026 | Sep 22, 2026 |
All 434 Endovia Health Sciences, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.